hb2198

Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases

Hinge Bio to receive $10 million upfront and is eligible to receive $95 million for the SLE indication and additional…

4 hours ago